Optimal Tailored Treatment for H. Pylori Infection
Key facts
- Who runs it
- Incheon St.Mary's Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Sept 2020
- Ended
- 1 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
- Record updated
- 16 May 2024
- Why it stopped
- The study design was changed.
Who can take part
- Age
- 19 years to 79 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- consecutive subjects who underwent upper gastrointestinal endoscopy and who had a confirmed diagnosis of H pylori infection
Who cannot take part
- subjects who had previous gastric surgery
- subjects with serious concurrent illness
- subjects with a history of H pylori eradication
- subjects with a history of allergy to any one of the compounds in this study
- subjects younger than 18 years old
- subjects who were pregnant or lactating
- subjects who were administered antibiotics, bismuth, or PPIs in the 8 weeks preceding the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The efficacy of the current standard triple therapy is at an unacceptably low level. Resistance to antibiotics is suspected to be the major cause of the low efficacy of standard triple therapy. Point mutations in the 23S rRNA gene are known to be the primary mechanism of clarithromycin resistance against H pylori. Recently, a point mutation detection kit using a dual-priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) assay was introduced and made commercially available. The primary goal of our study was to compare the eradication rates of empirical therapy and tailored therapy. Specifically we examined the eradication rates of 7-d, 14-d empirical therapy with 7-d, 14-d tailored therapy. Our secondary goal was to examine the adverse events of each treatment, cost effectiveness of each treatment methods, and accuracy of DPO-PCR for detecting H. pylori resistance.
The 2 groups in the trial
- Empirical therapy for H. pylori infectionExisting treatment, for comparison
The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
Treatment: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
- Tailored therapy for H. pylori infectionTreatment being tested
The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
Treatment: Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimal Tailored Treatment for H. Pylori Infection According to the Presence of DPO-PCR Based Clarithromycin Resistance
- Record updated
- 16 May 2024